Bivas Bala


AIM: To evaluate the efficacy of intravitreal ranibizumab in chronic central serous chorioretinopathy associated with retinal pigment epithelial detachment. METHODS: In this retrospective study a total of 21 patients diagnosed with chronic central serous chorioretinopathy with pigment epithelial detachment were treated with intravitreal ranibizumab from Jan 2017 to Nov 2019 at Malda medical college, West Bengal, India. From the history sheet we were noted each patient's best spectacle corrected visual acuity. Measurement of central macular thickness and subfoveal choroidal thickness were recorded from OCT report. After getting informed consent all patient received intravitreal ranibizumab injection at monthly interval until central macular thickness reduced to normal.  Patient were followed up monthly interval for at least 6 months by measuring best corrected visual acuity and central macular thickness as well as subfoveal choroidal thickness. We were taken these data specially of 3 and 6 months for analysis. This data was analyzed statically by pair T test to determine the effectiveness of intravitreal ranibizumab in this condition. RESULTS: all patients showed statically significant improvement within 3 months in terms of best corrected visual acuity, central macular thickness as well as choroidal thickness (p=<0.001) and these were well maintained at 6 months. CONCLUSION: Intravitreal ranibizumab is a good therapeutic option in patients of chronic central retinopathy when it also associated with retinal pigment epithelial detachment.


Chronic central serous chorioretinopathy, pigment epithelial detachment, ranibizumab, choroidal neovascular membrane.

Full Text:



von Graefe A. Ueber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866;12:211–215.

Maumenee AE. Symposium: macular diseases, clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol. 1965;69:605–613.

Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63(Suppl):1–139.

Mudvari S, S Goff, et al. The natural history of pigment epithelial detachment associated with central serous chorioretinopathy. Retina 2007, 27(9), 1168-1173.

Jason Y Zhang, Caio V Regateiri et al. Micro-structural features of active acute and chronic central serous chorioretinopathy on spectral domain optical coherence tomography and correlation with autofluorescence imaging. Investigate ophthalmology and visual science. 2012.53:828.

Shangli Ji, Yemei Wei, Jiansu Chen, Shibo Tang. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis. International Journal of Clinical Pharmacy. June 2017, Volume 39, Issue 3, pp 514–521

Kim M, Lee SC, Lee SJ et al. Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica. 2013; 229:152-157.

Spitznas M. Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol. 1986;224:321–324

Chen WM, Laity, liu DT et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization seceondary to central serous chorioretinopathy, seceondary to punctate inner choroidopathy or of idiopathic origin. Am J ophthalmology. 2007;143(6): 977-83.

Schaal KB, Hoeh AE et al. Intravitreal bevacizumab for treatment of chronic central serous chorioretinopathy. Eur J Ophthalmol. 2009; 19: 613-617

Lantry LE. Ranibizumab, a mAb against VEGF-A for the potential treatment of age related macular degeneration and other ocular complication. Curr Opin Mol Ther. 2007;9:592-602.

Tekin K, Sekeroglu MA, Cankaya AB, Teke MY, Doguizi S, Yilmazbas P. Intravitreal Bevacizumab and Ranibizumab in the Treatment of Acute Central Serous Chorioretihopathy: A Single Center Retrospective Study. Semin Ophthalmol. 2018;33(2):265-270.


  • There are currently no refbacks.